• JAMA Author Interviews

  • 著者: JAMA Network
  • ポッドキャスト

JAMA Author Interviews

著者: JAMA Network
  • サマリー

  • Interviews with leading researchers and thinkers in health care about practice-changing research, innovations, and the most pressing issues facing medicine and health care today from JAMA, the Journal of the American Medical Association.
    2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
    続きを読む 一部表示

あらすじ・解説

Interviews with leading researchers and thinkers in health care about practice-changing research, innovations, and the most pressing issues facing medicine and health care today from JAMA, the Journal of the American Medical Association.
2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
エピソード
  • The Impacts of Severe Maternal Morbidity
    2024/11/25

    A new JAMA study examines the association between severe maternal morbidity in a first birth and the probability of a subsequent birth. Authors Neda Razaz, PhD, and Eleni Tsamantioti, MD, MMedSc, both from the Karolinska Institute in Sweden, discuss this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH.

    Related Content:

    • Association of Severe Maternal Morbidity With Subsequent Birth
    • Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman’s Choice
    続きを読む 一部表示
    13 分
  • Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)
    2024/11/18

    Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration.

    Related Content:

    • Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
    続きを読む 一部表示
    14 分
  • Intratracheal Budesonide for Extremely Preterm Infants
    2024/11/11

    Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH.

    Related Content:

    • Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants
    続きを読む 一部表示
    8 分

JAMA Author Interviewsに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。